Ceredex Value Advisors LLC Acquires 281,750 Shares of Bruker Corporation $BRKR

Ceredex Value Advisors LLC raised its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 131.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 496,000 shares of the medical research company’s stock after buying an additional 281,750 shares during the quarter. Ceredex Value Advisors LLC’s holdings in Bruker were worth $16,115,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Orbis Allan Gray Ltd bought a new position in Bruker during the second quarter worth $192,735,000. AQR Capital Management LLC boosted its holdings in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the period. Edmond DE Rothschild Holding S.A. bought a new stake in Bruker in the 2nd quarter valued at $62,032,000. Norges Bank acquired a new stake in Bruker in the 2nd quarter worth $44,459,000. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in shares of Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after purchasing an additional 796,510 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Stock Performance

NASDAQ:BRKR opened at $37.19 on Tuesday. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $56.22. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $5.66 billion, a PE ratio of -247.93, a price-to-earnings-growth ratio of 2.20 and a beta of 1.19. The firm has a 50-day moving average price of $44.45 and a 200 day moving average price of $41.08.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The company had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s payout ratio is currently -133.33%.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $49.20, for a total value of $98,400.00. Following the sale, the vice president directly owned 128,443 shares in the company, valued at $6,319,395.60. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 27.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of research analyst reports. Barclays cut their price objective on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Bank of America upped their price target on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 15th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. The Goldman Sachs Group decreased their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a report on Friday, February 13th. Finally, Rothschild & Co Redburn set a $60.00 target price on Bruker in a research note on Thursday, November 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Bruker presently has a consensus rating of “Hold” and a consensus target price of $50.38.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.